Rac1-mediated effects of HMG-CoA reductase inhibitors (statins) in cardiovascular disease

Antioxidants and Redox Signaling

Volumn 20, Issue 8, 2014, Pages 1238-1250

  Adam, Oliver ^a   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR CIRCULATION; HEART ATRIA; HEART VENTRICLES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIUM; ORGAN SPECIFICITY; RAC1 GTP-BINDING PROTEIN;

EID: 84894498866     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5526     Document Type: Review

References (137)

1. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 248: 1465-1477, 1982.
2. Adam O, Frost G, Custodis F, Sussman MA, Schä fers HJ, Böhm M, and Laufs U. Role of Rac1 GTPase activation in atrial fibrillation. J Am oll Cardiol 50: 359-367, 2007.
3. Adam O, Hagel M, Theobald K, Böhm M, and Laufs U. Inhibitory effect of estrogen on Rac1-expression in monocytes. Biochem Biophys Res Commun 386: 45-49, 2009.
4. Adam O and Laufs U. Antioxidative effects of statins. Arch Toxicol 82: 885-892, 2008.
5. Adam O, Lavall D, Theobald K, Hohl M, Grube M, Ameling S, Sussman MA, Rosenkranz S, Kroemer HK, Schäfers HJ, Böhm M, and Laufs U. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol 55: 469-480, 2010.
6. Adam O, Lohfelm B, Thum T, Gupta SK, Puhl SL, Schäfers HJ, Böhm M, and Laufs U. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 107: 278, 2012.
7. Adam O, Theobald K, Lavall D, Grube M, Kroemer HK, Ameling S, Schäfers HJ, Böhm M, and Laufs U. Increased lysyl oxidase expression and collagen crosslinking during atrial fibrillation. J Mol Cell Cardiol 50: 678-685, 2011.
8. Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Zhu W, Kadowaki T, and Yazaki Y. Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res 84: 458-466, 1999.
9. Aikawa R, Nawano M, Gu Y, Katagiri H, Asano T, Zhu W, Nagai R, and Komuro I. Insulin prevents cardiomyocytes from oxidative stress-induced apoptosis through activation of PI3 kinase/Akt. Circulation 102: 2873-2879, 2000.
10. Akar FG, Nass RD, Hahn S, Cingolani E, Shah M, Hesketh GG, DiSilvestre D, Tunin RS, Kass DA, and Tomaselli GF. Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol 293: H1223-H1230, 2007.
11. Akar FG, Spragg DD, Tunin RS, Kass DA, and Tomaselli GF. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res 95: 717-725, 2004.
12. Akilesh S, Suleiman H, Yu H, Stander MC, Lavin P, Gbadegesin R, Antignac C, Pollak M, Kopp JB, Winn MP, and Shaw AS. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Clin Invest 121: 4127-4137, 2011.
13. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol 62: 10J-15J, 1988.
14. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, and Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl- coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77: 3957-3961, 1980.
15. Allessie M, Ausma J, and Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54: 230-246, 2002.
16. Alom-Ruiz SP, Anilkumar N, and Shah AM. Reactive oxygen species and endothelial activation. Antioxid Redox Signal 10: 1089-1100, 2008.
17. Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, Antonopoulos AS, Demosthenous M, Marinou K, Hale A, Paschalis A, Psarros C, Triantafyllou C, Bendall J, Casadei B, Stefanadis C, and Channon KM. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 124: 335-345, 2011.
18. Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, Antonopoulos AS, Demosthenous M, Miliou A, Psarros C, Marinou K, Sfyras N, Economopoulos G, Casadei B, Channon KM, and Stefanadis C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPHoxidase activity. Circulation 122: S66-S73, 2010.
19. Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos A, Marinou K, Nahar K, Jayaram R, Tousoulis D, Bakogiannis C, Sayeed R, Triantafyllou C, Koumallos N, Psarros C, Miliou A, Stefanadis C, Channon KM, and Casadei B. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol 59: 60-70, 2012.
20. Antonopoulos AS, Margaritis M, Shirodaria C, and Antoniades C. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost 108: 840-848, 2012.
21. Barringhaus KG and Zamore PD. MicroRNAs: regulating a change of heart. Circulation 119: 2217-2224, 2009.
22. Bendall JK, Cave AC, Heymes C, Gall N, and Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105: 293-296, 2002.
23. Boengler K, Schulz R, and Heusch G. Connexin 43 signalling and cardioprotection 1. Heart 92: 1724-1727, 2006.
24. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, Chavakis E, Potente M, Tjwa M, Urbich C, Zeiher AM, and Dimmeler S. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324: 1710-1713, 2009.
25. Boon RA, Seeger T, Heydt S, Fischer A, Hergenreider E, Horrevoets AJ, Vinciguerra M, Rosenthal N, Sciacca S, Pilato M, van Heijningen P, Essers J, Brandes RP, Zeiher AM, and Dimmeler S. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res 109: 1115-1119, 2011.
26. Brown JH, Del Re DP, and Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 98: 730-742, 2006.
27. Burstein B and Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51: 802-809, 2008.
28. Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840-844, 2000.
29. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, Dudley SC, Jr., Harrison DG, and Langberg JJ. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106: 2854-2858, 2002.
30. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy PM, Bauer JA, and Van Wagoner DR. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 89: E32-E38, 2001.
31. Chello M, Goffredo C, Patti G, Candura D, Melfi R, Mastrobuoni S, Di Sciascio G, and Covino E. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cardiothorac Surg 28: 805-810, 2005.
32. Cheng XW, Kuzuya M, Sasaki T, Inoue A, Hu L, Song H, Huang Z, Li P, Takeshita K, Hirashiki A, Sato K, Shi GP, Okumura K, and Murohara T. Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin. J Hypertens 29: 542-552, 2011.
33. Clerk A, Cullingford TE, Fuller SJ, Giraldo A, Markou T, Pikkarainen S, and Sugden PH. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol 212: 311-322, 2007.
34. Collins R, Armitage J, Parish S, Sleight P, and Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363: 757-767, 2004.
35. Crouse JR, 3rd, Byington RP, and Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 138: 11-24, 1998.
36. Custodis F, Eberl M, Kilter H, Böhm M, and Laufs U. Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy. Cardiovasc Res 71: 342-351, 2006.
37. Dalkara T, Yoshida T, Irikura K, and Moskowitz MA. Dual role of nitric oxide in focal cerebral ischemia. Neuropharmacology 33: 1447-1452, 1994.
38. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, Bieringer M, Gulba D, Dietz R, Luft FC, and Haller H. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 104: 576-581, 2001.
39. Dernellis J and Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 150: 1064, 2005.
40. Endres M and Laufs U. Discontinuation of statin treatment in stroke patients. Stroke 37: 2640-2643, 2006.
41. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, and Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95: 8880-8885, 1998.
42. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, and Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 83: 683-690, 1998.
43. Falk RH. Atrial fibrillation. N Engl J Med 344: 1067-1078, 2001.
44. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, and Zamorano JL. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 114: e257-e354, 2006.
45. Girmatsion Z, Biliczki P, Bonauer A, Wimmer-Greinecker G, Scherer M, Moritz A, Bukowska A, Goette A, Nattel S, Hohnloser SH, and Ehrlich JR. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm 6: 1802-1809, 2009.
46. Gissi HFI, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, and Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial. Lancet 372: 1231-1239, 2008.
47. Goldstein JL and Brown MS. Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
48. Gregg D, Rauscher FM, and Goldschmidt-Clermont PJ. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. Am J Physiol Cell Physiol 285: C723-C734, 2003.
49. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
50. Hacohen N, Kramer S, Sutherland D, Hiromi Y, and Krasnow MA. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 92: 253-263, 1998.
51. Hall A. Rho GTPases and the actin cytoskeleton. Science 279: 509-514, 1998.
52. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100: 2153-2157, 1997.
53. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, and Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45: 1832-1839, 2005.
54. Hornstra IK, Birge S, Starcher B, Bailey AJ, Mecham RP, and Shapiro SD. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J Biol Chem 278: 14387-14393, 2003.
55. Kannel WB, Castelli WP, Gordon T, and McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 74: 1-12, 1971.
56. Kawarazaki W, Nagase M, Yoshida S, Takeuchi M, Ishizawa K, Ayuzawa N, Ueda K, and Fujita T. Angiotensin IIand salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol 23: 997-1007, 2012.
57. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, and Group C. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357: 2248-2261, 2007.
58. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, and Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3: 249-254, 1997.
59. Kou R and Michel T. Epinephrine regulation of the endothelial nitric-oxide synthase: roles of RAC1 and beta3-adrenergic receptors in endothelial NO signaling. J Biol Chem 282: 32719-32729, 2007.
60. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, and Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689, 2005.
61. Kuehbacher A, Urbich C, Zeiher AM, and Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 101: 59-68, 2007.
62. Kumagai K, Nakashima H, and Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 62: 105-111, 2004.
63. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, and Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-1435, 2005.
64. Lassegue B and Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 30: 653-661, 2010.
65. Laufs U, Adam O, Strehlow K, Wassmann S, Konkol C, Laufs K, Schmidt W, Böhm M, and Nickenig G. Downregulation of Rac-1 GTPase by Estrogen. J Biol Chem 278: 5956-5962, 2003.
66. Laufs U, Custodis F, and Böhm M. Who does not need a statin: too late in end-stage renal disease or heart failure? Heart 94: 1138-1140, 2008.
67. Laufs U, Kilter H, Konkol C, Wassmann S, Böhm M, and Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 53: 911-920, 2002.
68. Laufs U, La Fata L, and Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxiamediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272: 31725-31729, 1997.
69. Laufs U, La Fata V, Plutzky J, and Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135, 1998.
70. Laufs U and Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998.
71. Lee RC, Feinbaum RL, and Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
72. Lee TM, Chou TF, and Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol 40: 868-874, 2002.
73. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, and Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100: 178-184, 1999.
74. Lefer AM, Scalia R, and Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 49: 281-287, 2001.
75. Lezoualc'h F, Metrich M, Hmitou I, Duquesnes N, and Morel E. Small GTP-binding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol 44: 623-632, 2008.
76. Li D, Fareh S, Leung TK, and Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort 1. Circulation 100: 87-95, 1999.
77. Li JM, Gall NP, Grieve DJ, Chen M, and Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40: 477-484, 2002.
78. Li JM and Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 287: R1014-R1030, 2004.
79. Liao JK. Endothelium and acute coronary syndromes. Clin Chem 44: 1799-1808, 1998.
80. Liao JK and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118, 2005.
81. Loffredo L, Angelico F, Perri L, and Violi F. Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and metaanalysis. BMC Cardiovasc Disord 12: 107, 2012.
82. Lopez B, Querejeta R, Gonzalez A, Beaumont J, Larman M, and Diez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 53: 236-242, 2009.
83. Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F, Shan H, Luo X, Bai Y, Sun L, Song W, Xu C, Wang Z, and Yang B. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 122: 2378-2387, 2010.
84. Maack C, Kartes T, Kilter H, Schäfers HJ, Nickenig G, Böhm M, and Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of Rac1-GTPase and represents a target for statin treatment. Circulation 108: 1567-1574, 2003.
85. MacCarthy PA, Grieve DJ, Li JM, Dunster C, Kelly FJ, and Shah AM. Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation 104: 2967-2974, 2001.
86. Maki JM, Rasanen J, Tikkanen H, Sormunen R, Makikallio K, Kivirikko KI, and Soininen R. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 106: 2503-2509, 2002.
87. Marin F, Pascual DA, Roldan V, Arribas JM, Ahumada M, Tornel PL, Oliver C, Gomez-Plana J, Lip GY, and Valdes M. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 97: 55-60, 2006.
88. Maron DJ, Fazio S, and Linton MF. Current perspectives on statins. Circulation 101: 207-213, 2000.
89. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, and Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104: 174-180, 2001.
90. Moldovan L, Mythreye K, Goldschmidt-Clermont PJ, and Satterwhite LL. Reactive oxygen species in vascular endothelial cell motility. Roles of NAD(P)H oxidase and Rac1. Cardiovasc Res 71: 236-246, 2006.
91. Munzel T, Sayegh H, Freeman BA, Tarpey MM, and Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95: 187-194, 1995.
92. Nagase M. Role of Rac1 GTPase in salt-sensitive hypertension. Curr Opin Nephrol Hypertens 22: 148-155, 2013.
93. Nagase M and Fujita T. Role of Rac1-mineralocorticoidreceptor signalling in renal and cardiac disease. Nat Rev Nephrol 9: 86-98, 2013.
94. Nakagawa H, Miki H, Ito M, Ohashi K, Takenawa T, and Miyamoto S. N-WASP, WAVE and Mena play different roles in the organization of actin cytoskeleton in lamellipodia. J Cell Sci 114: 1555-1565, 2001.
95. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415: 219-226, 2002.
96. Nattel S, Allessie M, and Haissaguerre M. Spotlight on atrial fibrillation-the 'complete arrhythmia'. Cardiovasc Res 54: 197-203, 2002.
97. Nawawi H, Osman NS, Annuar R, Khalid BA, and Yusoff K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 169: 283-291, 2003.
98. Node K, Fujita M, Kitakaze M, Hori M, and Liao JK. Shortterm statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108: 839-843, 2003.
99. Ozaydin M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M, and Altinbas A. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 97: 1490-1493, 2006.
100. Page RL. Clinical practice. Newly diagnosed atrial fibrillation. N Engl J Med 351: 2408-2416, 2004.
101. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 21: 3-5, 2001.
102. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, and Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114: 1455-1461, 2006.
103. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 363: 62-64, 2004.
104. Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, Alp NJ, Schotten U, and Casadei B. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 124: 1107-1117, 2011.
105. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N, and Yokoyama M. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154: 87-96, 2001.
106. Rucker-Martin C, Milliez P, Tan S, Decrouy X, Recouvreur M, Vranckx R, Delcayre C, Renaud JF, Dunia I, Segretain D, and Hatem SN. Chronic hemodynamic overload of the atria is an important factor for gap junction remodeling in human and rat hearts. Cardiovasc Res 72: 69-79, 2006.
107. Sawada N, Kim HH, Moskowitz MA, and Liao JK. Rac1 is a critical mediator of endothelium-derived neurotrophic activity. Sci Signal 2: ra10, 2009.
108. Sawada N, Li Y, and Liao JK. Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Curr Opin Pharmacol 10: 116-121, 2010.
109. Sawada N, Salomone S, Kim HH, Kwiatkowski DJ, and Liao JK. Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1. Circ Res 103: 360-368, 2008.
110. Selvakumar B, Hess DT, Goldschmidt-Clermont PJ, and Stamler JS. Co-regulation of constitutive nitric oxide synthases and NADPH oxidase by the small GTPase Rac. FEBS Lett 582: 2195-2202, 2008.
111. Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, Kawarazaki W, Takeuchi M, Ayuzawa N, Miyoshi J, Takai Y, Ishikawa A, Shimosawa T, Ando K, Nagase M, and Fujita T. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 121: 3233-3243, 2011.
112. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, Miyoshi J, Takai Y, and Fujita T. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 14: 1370-1376, 2008.
113. Shiroshita-Takeshita A, Schram G, Lavoie J, and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110: 2313-2319, 2004.
114. Siu CW, Lau CP, and Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92: 1343-1345, 2003.
115. Smith-Mungo LI, and Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol 16: 387-398, 1998.
116. Sundaresan M, Yu ZX, Ferrans VJ, Sulciner DJ, Gutkind JS, Irani K, Goldschmidt-Clermont PJ, and Finkel T. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J 318 (Pt 2): 379-382, 1996.
117. Sussman MA, Welch S, Walker A, Klevitsky R, Hewett TE, Price RL, Schaefer E, and Yager K. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest 105: 875-886, 2000.
118. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, and Liao JK. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108(10) 1429-1437, 2001.
119. Tan W, Palmby TR, Gavard J, Amornphimoltham P, Zheng Y, and Gutkind JS. An essential role for Rac1 in endothelial cell function and vascular development. FASEB J 22: 1829-1838, 2008.
120. Thorburn A, Thorburn J, Chen SY, Powers S, Shubeita HE, Feramisco JR, and Chien KR. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. J Biol Chem 268: 2244-2249, 1993.
121. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, and Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980-984, 2008.
122. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Pitsavos C, Vlachopoulos C, Panagiotakos D, and Stefanadis C. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 178: 359-363, 2005.
123. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, and Iguchi A. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104: 376-379, 2001.
124. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, and Gullestad L. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 93: 780-782, 2004.
125. Twigg SM, Joly AH, Chen MM, Tsubaki J, Kim HS, Hwa V, Oh Y, and Rosenfeld RG. Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation endproducts in human dermal fibroblasts. Endocrinology 143: 1260-1269, 2002.
126. Ushio-Fukai M and Urao N. Novel role of NADPH oxidase in angiogenesis and stem/progenitor cell function. Antioxid Redox Signal 11: 2517-2533, 2009.
127. Van AL and D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 11: 2295-2322, 1997.
128. Verhaar MC, Westerweel PE, van Zonneveld AJ, and Rabelink TJ. Free radical production by dysfunctional eNOS. Heart 90: 494-495, 2004.
129. Wang CY, Liu PY, and Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14: 37-44, 2008.
130. Wang Z, Lu Y, and Yang B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc Res 89: 710-721, 2011.
131. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G, Rosen R, Böhm M, and Nickenig G. HMGCoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37: 1450-1457, 2001.
132. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Böhm M, and Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59: 646-654, 2001.
133. Xiao L, Pimentel DR, Wang J, Singh K, Colucci WS, and Sawyer DB. Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 282: C926-C934, 2002.
134. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H, and Sen L. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109: 363-368, 2004.
135. Yang B, Lu Y, and Wang Z. Control of cardiac excitability by microRNAs. Cardiovasc Res 79: 571-580, 2008.
136. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, and Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92: 1379-1383, 2003.
137. Zhou Q and Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des 15: 467-478, 2009.